Viking Therapeutics, Inc. (VKTX) stock
Close on Nov 12, 2026Market cap $3.52BP/E –Yield –
Viking Therapeutics, Inc. reported revenue of $0 for the twelve months to Sep 30, 2026. At the latest close the market valued the company at $3.52B.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $3.52B
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 5.98
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $0
- Net income
- -$627.20M
- EPS, diluted
- -$5.40
- Book value per share
- $4.99
- Diluted shares
- 118M
Trading
- Next earnings
- Feb 10, 2027 (estimated, during market hours)
- Previous close
- $28.44
- Open
- $27.91
- Day's range
- $27.49 – $28.55
- Volume
- 2,190,813
- Average volume (20 days)
- 4,139,147
- Index membership
- Russell 1000 (since Sep 2024), Russell 3000 (since Aug 2023)
- Beta (5 years)
- 1.57
- 52-week range
- $23.82 – $43.15
- RSI (14 days)
- 52.6
- Volatility (1 year)
- 69.3%
- Relative volume
- 0.64×
- WACC
- 12.7%
On 1 of our idea list: Most shorted (a warning list)
Index membership is inferred from the holdings of funds that track each index (IWB, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2015, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | VKTX | S&P 500 | Difference | VKTX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -2.7% | -2.7% | +0.0 pts | ||
| 3 months | -18.9% | -1.7% | −17.2 pts | ||
| Year to date | -21.6% | +11.9% | −33.5 pts | ||
| 1 year | -32.4% | +12.0% | −44.4 pts | ||
| 3 years | +182.0% | +78.2% | +103.8 pts | +41.3% | +21.2% |
| 5 years | +348.5% | +73.2% | +275.2 pts | +35.0% | +11.6% |
| 10 years | +2407.0% | +309.6% | +2097.4 pts | +38.0% | +15.1% |
Thirteen years at a glance
Fiscal years 2013 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Press releases
Releases Viking Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- News
- Results
- Results
- Results
- Results
About Viking Therapeutics
Pharmaceutical Preparations
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that focuses on developing therapies for metabolic and endocrine disorders. Its product pipeline includes VK2735, a dual GLP-1 and GIP receptor agonist being evaluated in subcutaneous and oral formulations for obesity and metabolic conditions. The company is also developing VK2809, an orally available thyroid hormone receptor beta agonist targeting non-alcoholic steatohepatitis, and VK0214, an orally available thyroid hormone receptor beta agonist for X-linked adrenoleukodystrophy. Additionally, its pipeline includes VK5211, a selective androgen receptor modulator studied for recovery following hip fracture surgery, as well as an internally developed dual amylin and calcitonin receptor agonist program.
Company profile, executives and historyViking Therapeutics stock: common questions
What is Viking Therapeutics's stock price?
VKTX closed at $27.58 on Nov 12, 2026, down 3.02% on the day. Over the past 52 weeks it traded between $23.82 and $43.15.
What is Viking Therapeutics's market cap?
Viking Therapeutics was worth $3.52B at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is VKTX's P/E ratio?
Viking Therapeutics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$5.40), so it has no meaningful P/E ratio.
How much revenue does Viking Therapeutics make?
Viking Therapeutics reported revenue of $0 for the twelve months to Sep 30, 2026.
Does Viking Therapeutics pay a dividend?
No. Viking Therapeutics has not paid a cash dividend over the last twelve months.
When does Viking Therapeutics report earnings next?
Viking Therapeutics is expected to report Q4 FY2026 results on Feb 10, 2027, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has VKTX stock performed over the past year?
Including dividends, VKTX returned -32.4% over the past year, against +12.0% for the S&P 500.
How many VKTX shares are sold short?
24M shares were sold short at the latest FINRA report, 19.48% of the float, or 5.4 days of average trading volume.
Who are Viking Therapeutics's competitors?
Companies most similar to Viking Therapeutics by business, industry and size include VTVT, AARD, SEPN, BMEA, MBX.
See a number that looks wrong?